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The prothrombotic mediator thromboxane A2 is derived from arachidonic acid metabolism through the
cyclooxygenase and thromboxane synthase pathways, and transduces its effect through the thromboxane
prostanoid (TP) receptor. The aim of this study was to determine the effect of the TP receptor antagonist
and thromboxane synthase inhibitor EV-077 on inflammatory markers in human umbilical vein endothe-
lial cells and on human coronary artery smooth muscle cell proliferation. To this end, mRNA levels of dif-
ferent proinflammatory mediators were studied by real time quantitative PCR, supernatants were
analyzed by enzyme immune assay, and cell proliferation was assessed usingWST-1. EV-077 significantly
decreased mRNA levels of ICAM-1 and PTX3 after TNFa incubation, whereas concentrations of 6-keto
PGF1a in supernatants of endothelial cells incubated with TNFa were significantly increased after EV-
077 treatment. Although U46619 did not alter coronary artery smooth muscle cell proliferation, this
thromboxane mimetic enhanced the proliferation induced by serum, insulin and growth factors, which
was significantly inhibited by EV-077. In conclusion, EV-077 inhibited TNFa-induced endothelial inflam-
mation and reduced the enhancement of smooth muscle cell proliferation induced by a thromboxane
mimetic, supporting that the thromboxane pathway may be associated with early atherosclerosis in
terms of endothelial dysfunction and vascular hypertrophy.
 2013 The Authors. Published by Elsevier Inc. Open access under CC BY license. 1. Introduction
Thromboxane A2 (TXA2), a member of the prostaglandin
cascade, is a potent prothrombotic mediator with profound effects
on vascular reactivity and platelet activation. This lipid mediator is
synthesized from arachidonic acid through the cyclooxygenase
(COX) pathway and a specific thromboxane synthase (TXAS). In
target cells, such as platelets, endothelial cells (ECs) and vascular
smooth muscle cells (SMCs), the biological responses of TXA2 are
transduced through the G-protein coupled cell membrane throm-
boxane receptor, denoted TP. Targeting TXA2 through the common
low-dose aspirin treatment for prevention of thrombosis relies onthe irreversible inhibition of COX-1 in platelets, which lack the
ability to resynthesize COX enzymes, leading to a selective inhibi-
tion of platelet TXA2 formation.
Thromboxane is released during vascular inflammation, such as
atherosclerosis [1] and vascular injury [2]. Interestingly, analysis of
human atherosclerotic lesions revealed that TXAS was expressed in
infiltrating macrophages, suggesting immune cells as a potentially
important source of TXA2, in addition to platelets [1]. The latter no-
tion has been supported by the association of the urinary throm-
boxane metabolite 11-dehydro TXB2 with systemic inflammation
[3]. Taken together, these findings open up for a role of thrombox-
ane in atherosclerosis and vascular injury, which goes beyond
platelet aggregation. In support of the latter notion, either genetic
or pharmacological targeting of the TP receptor reduces atheroscle-
rosis in hyperlipemic mice [4–9], an effect which is not observed
with aspirin treatment [10].
Thromboxane A2 and isoprostanes can stimulate endothelial TP
receptors and increase the expression of proinflammatory markers
such as ICAM-1 and VCAM-1 [6]. In animal models, antagonism of
the TP receptor preserves endothelium-dependent relaxation of
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endothelial function in patients with coronary artery disease by
addition of the TP receptor antagonist terutroban to aspirin [12].
Whereas the vasoconstrictive effect of TP receptor signaling is
well established [13,14], only few studies have addressed the
direct effects of thromboxane mimetics on human vascular SMCs.
In aortic subendothelial intimal cells isolated from autopsy mate-
rial by enzymatic digestion of atherosclerotic plaques, the stable
TXA2 analogue U46619 stimulated [3H]thymidine uptake [15],
suggesting that TP receptor signaling may transduce SMC prolif-
eration. However, animal studies have generated conflicting
results about the role of TXA2 signaling in vascular SMC growth.
In an initial study, 9,11-epithio-11,12-methano-TXA2 (STA2)
stimulated DNA synthesis in rat vascular SMCs derived from nor-
motensive WKY rats, but not in those derived from spontaneously
hypertensive rats (SHR) [16]. Whereas the stimulation of SMC
proliferation was confirmed by subsequent studies of different
thromboxane mimetics, such as U46619, STA2 or carbocyclic
TXA2 (CTA2) [17–19], other investigators reported that U46619
did not alter rat aortic SMC proliferation [20,21]. Nevertheless,
the response to U46619 may be dose-dependent [22] and may
vary whether or not experiments were performed in the presence
of other growth stimuli.
EV-077 is a reversible dual TP receptor antagonist and throm-
boxane synthase inhibitor, which inhibits platelet aggregation both
in vitro in response to either arachidonic acid or U46619 [23–25]
and after oral administration [26]. However, the effects of EV-077
on human endothelial and vascular smooth muscle cells have not
previously been examined. Based on the above cited findings, the
aim of the present study was to determine the effects of EV-077
on inflammatory markers in human umbilical vein endothelial
cells (HUVEC) and on human coronary artery SMC proliferation.2. Materials and methods
2.1. Materials
The TXA2 mimetic U46619 [(15S)-hydroxy-11a,9a-(epoxymet-
hano)-presta-5Z,13E-dienoic acid] was purchased from Cayman
Chem (Ann Arbor). TNFa was purchase from R&D Systems. The
reversible dual TP receptor antagonist and thromboxane synthase
inhibitor EV-077 was obtained from Evolva (Reinach, Switzerland).
2.2. Cell culture
Human umbilical vein endothelial cells (HUVEC) were pur-
chased from Lonza (Switzerland). HUVEC were cultured in
endothelial cell growth medium, EGM-2 (Lonza), and maintained
at 37 C in a humidified atmosphere containing 5% CO2. Cells were
used at passages 2–4. Human coronary artery SMC was purchased
from Clonetics (Cambrex Bio Science, Walkersville, MD), and
cultured in SmGM2 kit medium and used at passages 5–8 as
previously described [27].
2.3. HUVEC incubation
HUVEC were seeded at 67,500 cells/flask in either gelatin-
coated T25 in EGM (corresponding to EGM-2 without FBS and sup-
plements) for PCR experiments, or on gelatin-coated 24-well plates
(Corning) in EGM for EIA analysis. After 2–4 days, cell medium was
replaced by EBM in the absence or presence of EV-077 at different
concentrations (10, 100, 300 or 600 nM). After 1 h of preincubation,
either vehicle or TNFa (1 ng/ml) was added into the T25 flasks.
Then, cells were stimulated with TNFa (1 ng/ml) for 6 h (still in
the presence of EV-077).2.4. SMC incubation
At 80% confluence, the SMCs were trypsinized and resuspended
in either DMEM supplemented with 2% FCS (‘‘low serum media’’),
or in SmGM2 kit medium containing 5% FCS, 2 ng/ml FGF,
0.5 ng/ml EGF, 5 lg/ml insulin (‘‘growth factor media’’).
Subsequently, 5000 cells in 200 lL were added to each well in a
96-well plate and left to adhere overnight. Either vehicle or
EV-077 (50 nM, 500 nM, 5 lM) was added to the wells 1 h before
U46619 at different concentrations (0.1 nM–10 lM) and incubated
for another 48 h. All experiments were repeated 3–5 times for each
experimental condition.2.5. Real time RT-PCR
After the incubation (cf. supra), cell medium was discarded and
cells were washed twice with PBS. Total RNA extraction was per-
formed by using QIAGEN RNeasy mini Kit according to the protocol
provided by the manufacturer (QIAGEN). RNA concentration for
each sample was determined by Nanodrop Spectrophotometer
ND-100 (ISOGEN, Life Science). Reverse transcription was per-
formed using Transcriptor First Strand cDNA Synthesis Kit Roche
(Roche Applied Science). Transcript levels were determined by
quantitative reverse transcription polymerase chain reaction
(qRT-PCR). cDNA obtained by reverse transcription of total RNA
were diluted 100 times and 5 ll were mixed with 12.5 ll of Fast
start Universal SYBRGreen Master (Roche), 2.5 ll MilliQ water,
2.5 ll of diluted primer forward and 2.5 ll of diluted primer re-
verse to have an optimal and final concentration of 300 or
900 nM. PCRs were carried out in a real-time PCR cycler (Applied
Biosystems 7900HT Fast Real-time PCR System): a hot start at
95 C for 5 min was followed by 40 cycles at 95 C for 15 s and
65 C for 1 min. Samples were compared using the relative cycle
threshold (Ct) method. To normalize the load of cDNA for each
sample, RPL13 was used as the endogenous standard. Primer
sequences are listed in Supplementary Table 1.2.6. 6-Keto PGF1a enzyme immune assay
After the incubation (cf. supra), medium of each well was col-
lected and cell lysis was performed in NaOH 0.5 N for 30 min.
6-Keto PGF1a levels in cell culture media were determined
using a competitive assay (#515211, Cayman, USA). Results are
expressed in picograms of 6-ketoPGF1a reported to micrograms
of proteins measured by the Folin method (Folin–Ciocalteu’s
phenol reagent, Merck, Germany) in cell lysates.2.7. Measurements of SMC proliferation
SMC proliferation was evaluated using WST-1 reagent
(Chemicon) according to the manufacturer’s instructions as
previously described [27]. In brief, after replacement of phenol
red containing media by 200 lL transparent serum-supplemented
DMEM, 10 lL of diluted WST-1 reagent was added to each well at
the end of the 48 h incubation period. After 1 h incubation at 37 C,
the absorbance of the formazan dye formed was measured at
440 nm using a microplate reader.2.8. Data analysis
All results are expressed as mean ± SE. Statistically significant
differences were determined by a one-way analysis of variances
(ANOVA), followed by a Bonferroni post hoc test, for multiple com-
parisons. A p value of less than 0.05 was considered significant.
Fig. 2. Effects of EV-077 and TNFa on 6-keto PGF1a secretion by HUVEC after 6 h of
incubation. 6-Keto PGF1a secretion was evaluated using a specific EIA assay.
Results are expressed in picograms of 6-keto PGF1a reported to micrograms of
proteins measured by the Folin method on cell lysates. Data are means ± S.D. (n = 3).
Statistical analysis: one way ANOVA followed by Bonferroni, ⁄P < 0.05 vs. control.
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3.1. Effect of EV-077 on HUVEC gene expression induced by TNFa
A statistically significant increase in mRNA expression of all
genes of interest was observed upon TNFa stimulation, except
for IL-6 for which the increase did not reach statistical significance
(Fig. 1). For two of the studied genes of interest, ICAM-1 and PTX3,
mRNA levels were significantly decreased in the presence of EV-
077 from a concentration of 100 nM (10 nM had no effect). This
effect was however not concentration-dependent, since inhibition
was not increased at higher concentrations of EV-077 (300 and 600
nM; Fig. 1). EV-077 at the highest concentration (600 nM) did not
affect mRNA expression in the absence of TNFa.
3.2. Effect of EV-077 and TNFa on HUVEC 6-keto PGF1a secretion
Although neither EV-077 nor TNFa alone increased 6-keto
PGF1a secretion, the simultaneous incubation of TNFa with
EV-077 (600 nM) significantly increased 6-keto PGF1a secretion
(Fig. 2).Fig. 1. Effects of EV-077 on mRNA expression of genes of interest encoding inflammatory or oxidative markers. mRNA expression was evaluated by quantitative RT-PCR in
HUVEC after 6 h of TNFa stimulation. Data are means ± S.D. (n = 3). Statistical analysis: one way ANOVA followed by Bonferroni, versus control NS P > 0.05, ⁄P < 0.05,
⁄⁄P < 0.01, ⁄⁄⁄P < 0.001; versus TNFa $p < 0.05, $$p < 0.01.
Fig. 4. Effect of the dual TP receptor antagonist and thromboxane synthase
inhibitor EV-077 on the proliferation of human coronary artery smooth muscle cells
induced by U46619, assessed by WST-1 reagent (see text). All experiments were
performed in the presence of FCS (5%), FGF (2 ng/ml), EGF (0.5 ng/ml), and insulin
(5 lg/ml). Results (mean ± SE) are expressed as fold change compared with vehicle
treated cells (in the absence of U46619), n = 7. ⁄P < 0.05 vs. control at each
concentration.
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In the presence of growth factor media, the thromboxane
mimetic U46619 induced a bell-shaped concentration-dependent
increase in cell number as assessed by WST-1 (Fig. 3). The maximal
response was observed at U46619-concentration of 1 nM, and at
concentrations of 0.1 lM and higher, the absorbance did not signif-
icantly differ between U46619- and vehicle-treated cells (Fig. 3). In
contrast to those findings, U46619 did not significantly alter SMC
proliferation when experiments were performed in low serum
media (Fig. 3).
In the presence of growth factor media, the dual TP receptor
antagonist and thromboxane synthase inhibitor EV-077 signifi-
cantly and concentration-dependently inhibited the SMC prolifera-
tion induced by U46619 (Fig. 4).
4. Discussion
The present study points to a role of thromboxane signaling
through the TP receptor in cells that constitute the vascular wall,
in terms of proinflammatory transcription in endothelial cells
and vascular smooth muscle cell proliferation. These findings sup-
port a role of thromboxane/TP receptor pathway in alterations of
the vascular wall associated with early atherosclerosis.
TNFa is a proinflammatory stimulus in HUVECs [28], and
previous studies have shown that different TP receptor antagonists
inhibit proinflammatory transcription induced by either TNFa
or the thromboxane mimetic U46619 [29]. In the present
study, TNFa-induced ICAM-1, MCP-1, IL-8, COX-2, and PTX3 but
not IL-6 mRNA expression. Interestingly, EV-077 significantly
decreased TNFa-induced ICAM-1 and PTX3 mRNA expression,
whereas no significant effects on mRNA expression of the other
genes of interest were observed. These results suggest that TP
receptor signalling may be associated with a specific profile of
transcriptional activation in HUVECs.
Whereas the signalling pathways involved in this response
remains to be established, it should be taken into consideration
that several mediators may be involved in the observed
EV-077-induced effects on mRNA levels. In addition to TXA2,
the isoprostane 8-iso PGF2a, derived from free radical-induced
oxidation of arachidonic acid, signal through the TP receptor, and
EV-077 antagonizes also isoprostane-induced TP activation [23].
However, the EC activation by 8-iso PGF2a may differ from thatFig. 3. Effect of the TP receptor agonist U46619 on the proliferation of human
coronary artery smooth muscle cells, assessed by WST-1 reagent (see text).
Experiments were performed either in the presence of FCS (2%), or in the presence
of FCS (5%), FGF (2 ng/ml), EGF (0.5 ng/ml), and insulin (5 lg/ml). Results are
expressed as mean ± SE for n = 3–7 observations at each concentration. All points
were significantly different (P < 0.05) when comparing the two groups.induced by TXA2, as suggested by studies of leukocyte–EC interac-
tions [30]. Furthermore, prostacyclin (PIG2, Prostaglandin I2) is
formed from arachidonic acid mainly by the vascular endothelium
and is a local potent vasodilator and inhibitor of platelet aggrega-
tion. PIG2 is non-enzymatically hydrated to 6-keto PGF1a in ECs.
The present study revealed that HUVECs incubated with EV-077
released significantly higher amounts of 6-keto PGF1a in response
to TNFa, indicating an enhanced prostacyclin production which
is known to exert anti-inflammatory effects in ECs [31].
The increased cardiovascular risk associated with selective
COX-2 inhibitors has been attributed to an imbalance between
thromboxane and prostacyclin [9,32]. The present observations
that EV-077 did not significantly alter the TNFa-induced COX-2
expression and increased 6-keto PGF1a suggest that in addition
to TP receptor antagonism and TXA synthase inhibition, this mole-
cule may also restore the prostacyclin pathway in ECs. The notion
of beneficial effects of the TP receptor antagonist EV-077 on
endothelial function, which emerges from the present results, is
in line with previous studies of terutroban [11,12]. However the
clinical implications of these findings remain to be established,
since the latter TP receptor antagonist was shown not be superior
to aspirin in terms of cardiovascular outcome after 3.5 years
follow-up in the PERFORM trial [33].
In the vascular wall, both ECs and vascular SMCs express TP
receptors [9]. Whereas the thromboxane analogue U46619 did
not alter SMC proliferation when cultured in low serum, a signifi-
cant enhancement of proliferation was observed in the presence of
growth factors and insulin in the present study. These results
indicate that TP receptor signaling may not directly induce SMC
proliferation, but rather acts as an amplification factor for vascular
SMC proliferation in response to locally released mitogens.
Previously, TXA2 mimetics have been found to increase smooth
muscle cell mitogenesis in the presence of a number of different
growth stimuli, such as insulin [34], EGF, PDGF-BB [35,36], throm-
bin [37], oxidized LDL [38] or serum [15,18], supporting the notion
of thromboxane as an enhancer of proliferation. However, in
another study in which U46619 failed to stimulate bovine aortic
SMC growth per se, this thromboxane mimetic did not significantly
augment either PDGF- or EGF-induced proliferation [39], suggest-
ing that the proliferation response transduced through the TP
receptor may also depend on other factors.
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a significant enhancement of SMC proliferation only at low concen-
trations. This concentration-dependent response is supported by
previous studies for example in canine aortic SMC, which also
exhibited a bell-shaped concentration–response proliferation
curve [22]. However, in the latter study, maximal SMC prolifera-
tion, measured both by means of DNA synthesis and cell number,
was observed at a U46619 concentration of 10 lM [22], which is
substantially higher compared with the maximal effect observed
at 1 nM of U46619 in the present study. Taken together, these
findings suggest that human SMCs may be more sensitive to
thromboxane stimulation compared with animal cells. However,
methodological differences cannot be ruled out as the cause for
these differential concentration–response curves.
The U46619 induced enhancement of SMC proliferation was
significantly inhibited by EV-077 in the present study, supporting
that low concentrations of U46619 induced an enhancement of
SMC proliferation through TP receptor signaling and suggesting
that TP receptor antagonism may reduce vascular hypertrophy
associated with atherosclerosis. The latter notion has received sup-
port from animal models of hypertension and vascular injury in
which either pharmacological or genetic targeting of the TP recep-
tor in reduces vascular thickness [31,40]. Furthermore, increased
urinary concentrations of 11-dehydro TXB2 was recently demon-
strated to be associated an increased intima media thickness of
the carotid artery in subjects with obstructive sleep apnea [41].
The potent effects of the COX-pathway on the cardiovascular
system have implications for several cardiovascular diseases such
as atherosclerosis, restenosis, stroke, myocardial infarction
[8,9,32], and more recently also demonstrated for atrial fibrillation
[42]. In summary, the present study shows that the dual TP recep-
tor antagonist and thromboxane synthase inhibitor EV-077 inhib-
ited TNFa-induced endothelial inflammation and reduced the
enhancement of SMC proliferation induced by a thromboxane
mimetic. Taken together, these results provide support to the
notion that TP receptor signaling may be associated with early
atherosclerosis in terms of endothelial dysfunction and vascular
hypertrophy.
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